Literature DB >> 26584565

In reply to: Enalapril and the VEGFA gene: personalized medicine in hypertension therapy.

G H Oliveira-Paula1, R Lacchini2, J E Tanus-Santos3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26584565     DOI: 10.1007/s00228-015-1985-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  12 in total

1.  Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses.

Authors:  Franz Faul; Edgar Erdfelder; Axel Buchner; Albert-Georg Lang
Journal:  Behav Res Methods       Date:  2009-11

2.  Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril.

Authors:  G H Oliveira-Paula; R Lacchini; V Fontana; P S Silva; C Biagi; Jose E Tanus-Santos
Journal:  Eur J Clin Pharmacol       Date:  2015-05-24       Impact factor: 2.953

3.  Functional VEGF haplotypes affect the susceptibility to hypertension.

Authors:  V C Sandrim; M R Luizon; T C Izidoro-Toledo; E B Coelho; H Moreno; J E Tanus-Santos
Journal:  J Hum Hypertens       Date:  2011-12-22       Impact factor: 3.012

4.  Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers.

Authors:  Pamela S Silva; Vanessa Fontana; Ana C T Palei; Jonas T C Sertório; Celso Biagi; Jose Eduardo Tanus-Santos
Journal:  Eur J Clin Pharmacol       Date:  2011-02-09       Impact factor: 2.953

5.  Effect of genetic polymorphisms of vascular endothelial growth factor on left ventricular hypertrophy in patients with systemic hypertension.

Authors:  Riccardo Lacchini; Marcelo Rizzatti Luizon; Sandra Gasparini; Maria C Ferreira-Sae; Roberto Schreiber; Wilson Nadruz; Jose E Tanus-Santos
Journal:  Am J Cardiol       Date:  2013-11-09       Impact factor: 2.778

6.  The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis.

Authors:  Timothy D Henry; Brian H Annex; George R McKendall; Michael A Azrin; John J Lopez; Frank J Giordano; P K Shah; James T Willerson; Raymond L Benza; Daniel S Berman; C Michael Gibson; Alex Bajamonde; Amy Chen Rundle; Jennifer Fine; Edward R McCluskey
Journal:  Circulation       Date:  2003-03-18       Impact factor: 29.690

7.  Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension.

Authors:  Valeria C Sandrim; Ana C T Palei; Ricardo C Cavalli; Francielle M Araújo; Ester S Ramos; Geraldo Duarte; Jose E Tanus-Santos
Journal:  Mol Hum Reprod       Date:  2008-12-05       Impact factor: 4.025

8.  Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression.

Authors:  Carie S Facemire; Andrew B Nixon; Robert Griffiths; Herbert Hurwitz; Thomas M Coffman
Journal:  Hypertension       Date:  2009-08-03       Impact factor: 10.190

9.  Angiotensin-converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats.

Authors:  Jorge E Toblli; Gabriel Cao; Graciela DeRosa; Federico Di Gennaro; Pedro Forcada
Journal:  Am J Hypertens       Date:  2004-02       Impact factor: 2.689

10.  Role of bradykinin, nitric oxide, and angiotensin II type 2 receptor in imidapril-induced angiogenesis.

Authors:  Ping Li; Takahisa Kondo; Yasushi Numaguchi; Koichi Kobayashi; Mika Aoki; Natsuo Inoue; Kenji Okumura; Toyoaki Murohara
Journal:  Hypertension       Date:  2007-12-17       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.